Chondroitin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In biochemistry, '''chondroitin''' is a "mucopolysaccharide constituent of chondrin."<ref>{{MeSH}}</ref> ==References== <references/>) |
imported>Robert Badgett (Added clinical studies) |
||
| Line 1: | Line 1: | ||
In [[biochemistry]], '''chondroitin''' is a "mucopolysaccharide constituent of chondrin."<ref>{{MeSH}}</ref> | In [[biochemistry]], '''chondroitin''' is a "mucopolysaccharide constituent of chondrin."<ref>{{MeSH}}</ref> | ||
==Clinical studies== | |||
Chondroitin has been studied as a treatment for [[osteoarthritis]]. A [[meta-analysis]] of [[randomized controlled trial]]s found no benefit.<ref name="pmid17438317">{{cite journal |author=Reichenbach S, Sterchi R, Scherer M, ''et al'' |title=Meta-analysis: chondroitin for osteoarthritis of the knee or hip |journal=Ann. Intern. Med. |volume=146 |issue=8 |pages=580-90 |year=2007 |pmid=17438317 |url=http://www.annals.org/cgi/content/full/146/8/580|doi=}}</ref> This [[meta-analysis]] included the GAIT [[randomized controlled trial]] of Clegg et al that was sponsorered by the U.S. [[National Institutes of Health]].<ref name="pmid16495392">{{cite journal |author=Clegg DO, Reda DJ, Harris CL, ''et al'' |title=Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis |journal=N. Engl. J. Med. |volume=354 |issue=8 |pages=795–808 |year=2006 |month=February |pmid=16495392 |doi=10.1056/NEJMoa052771 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16495392&promo=ONFLNS19 |issn=}}</ref> A longer followup of the GAIT show no benefit from sodium chondroitin on reduction in loss of joint space width.<ref name="pmid18821708">{{cite journal |author=Sawitzke AD, Shi H, Finco MF, ''et al'' |title=The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial |journal=Arthritis Rheum. |volume=58 |issue=10 |pages=3183–91 |year=2008 |month=October |pmid=18821708 |doi=10.1002/art.23973 |url=http://dx.doi.org/10.1002/art.23973 |issn=}}</ref> | |||
A more recent trial is positive. A trial sponsored by the manufacturer reports less loss of joint space with chondroitins 4 and 6.<ref name="pmid19180484">{{cite journal |author=Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY |title=Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial |journal=Arthritis Rheum. |volume=60 |issue=2 |pages=524–33 |year=2009 |month=February |pmid=19180484 |doi=10.1002/art.24255 |url=http://dx.doi.org/10.1002/art.24255 |issn=}} [http://general-medicine.jwatch.org/cgi/content/full/2009/219/3 ''Trial registration not provided''. Summary at JournalWatch.org]</ref> | |||
{| class="wikitable" align="right" | |||
|+ Selected randomized controlled trials of [[chondroitin]] | |||
! rowspan="2"|Trial!! rowspan="2"|Patients!!rowspan="2"|Intervention!!rowspan="2"|Outcome!!colspan="2"|Results | |||
|- | |||
! Chondroitin!!Placebo | |||
|- | |||
| GAIT<ref name="pmid16495392"/><br/>2007 || 1583 patients with knee osteoarthritis|| 1200 mg of chondroitin sulfate daily|| Response of 20% decrease in WOMAC pain score<ref name="pmid3068365">{{cite journal |author=Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW |title=Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee |journal=J. Rheumatol. |volume=15 |issue=12 |pages=1833–40 |year=1988 |month=December |pmid=3068365 |doi= |url= |issn=}}</ref> at 24 weeks||All subjects: 65%<br/>Mild [[Osteoarthritis|OA]]: 67%<br/>Moderate/severe [[Osteoarthritis|OA]]: 61%‡||All subjects: 60%<br/>Mild [[Osteoarthritis|OA]]: 62%<br/>Moderate/severe [[Osteoarthritis|OA]]: 54%<br/> | |||
|- | |||
| GAIT<ref name="pmid18821708"/><br/>2008 || 1583 patients with knee osteoarthritis|| 1200 mg of chondroitin sulfate daily|| Loss of joint space width at two years|| 0.107 mm || 0.166 mm | |||
|- | |||
| Kahan<ref name="pmid19180484"/><br/>2009<br/>''Sponsored by manufacturer and trial registration not provided'' || 622 patients with knee osteoarthritis<br/>32% dropped out|| 800 mg of chondroitin sulfate daily|| Loss at minimum joint space width<br/>Used last observation carried forward for dropouts|| 0.07 mm†|| 0.31 mm | |||
|- | |||
| colspan="6"|† p < 0.05<br/>‡ All comparisons were [[Statistical significance|insignificant]] and less than occurred with [[celecoxib]]; however, the combination of [[glucosamine]] hydrochloride and chondroitin gave [[Statistical significance|significant]] 79% improvement among moderate/severe patients. | |||
|} | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 08:44, 3 March 2009
In biochemistry, chondroitin is a "mucopolysaccharide constituent of chondrin."[1]
Clinical studies
Chondroitin has been studied as a treatment for osteoarthritis. A meta-analysis of randomized controlled trials found no benefit.[2] This meta-analysis included the GAIT randomized controlled trial of Clegg et al that was sponsorered by the U.S. National Institutes of Health.[3] A longer followup of the GAIT show no benefit from sodium chondroitin on reduction in loss of joint space width.[4]
A more recent trial is positive. A trial sponsored by the manufacturer reports less loss of joint space with chondroitins 4 and 6.[5]
| Trial | Patients | Intervention | Outcome | Results | |
|---|---|---|---|---|---|
| Chondroitin | Placebo | ||||
| GAIT[3] 2007 |
1583 patients with knee osteoarthritis | 1200 mg of chondroitin sulfate daily | Response of 20% decrease in WOMAC pain score[6] at 24 weeks | All subjects: 65% Mild OA: 67% Moderate/severe OA: 61%‡ |
All subjects: 60% Mild OA: 62% Moderate/severe OA: 54% |
| GAIT[4] 2008 |
1583 patients with knee osteoarthritis | 1200 mg of chondroitin sulfate daily | Loss of joint space width at two years | 0.107 mm | 0.166 mm |
| Kahan[5] 2009 Sponsored by manufacturer and trial registration not provided |
622 patients with knee osteoarthritis 32% dropped out |
800 mg of chondroitin sulfate daily | Loss at minimum joint space width Used last observation carried forward for dropouts |
0.07 mm† | 0.31 mm |
| † p < 0.05 ‡ All comparisons were insignificant and less than occurred with celecoxib; however, the combination of glucosamine hydrochloride and chondroitin gave significant 79% improvement among moderate/severe patients. | |||||
References
- ↑ Anonymous (2024), Chondroitin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Reichenbach S, Sterchi R, Scherer M, et al (2007). "Meta-analysis: chondroitin for osteoarthritis of the knee or hip". Ann. Intern. Med. 146 (8): 580-90. PMID 17438317. [e]
- ↑ 3.0 3.1 Clegg DO, Reda DJ, Harris CL, et al (February 2006). "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis". N. Engl. J. Med. 354 (8): 795–808. DOI:10.1056/NEJMoa052771. PMID 16495392. Research Blogging.
- ↑ 4.0 4.1 Sawitzke AD, Shi H, Finco MF, et al (October 2008). "The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial". Arthritis Rheum. 58 (10): 3183–91. DOI:10.1002/art.23973. PMID 18821708. Research Blogging.
- ↑ 5.0 5.1 Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY (February 2009). "Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial". Arthritis Rheum. 60 (2): 524–33. DOI:10.1002/art.24255. PMID 19180484. Research Blogging. Trial registration not provided. Summary at JournalWatch.org
- ↑ Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (December 1988). "Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee". J. Rheumatol. 15 (12): 1833–40. PMID 3068365. [e]